WALTHAM, Mass.--(BUSINESS WIRE)--Fresenius Medical Care (NYSE: FMS), the world’s largest provider of dialysis products and services, announced that Franklin W. Maddux, M.D., FACP, has been appointed Chief Medical Officer (CMO) for Fresenius Medical Care North America (FMCNA), effective December 12, 2011. In this role he will also be responsible for Clinical and Scientific Affairs.
Dr. Maddux will report to Rice Powell, Chief Executive Officer of Fresenius Medical Care North America and Deputy Chairman of the Management Board, who commented: “We are very excited to have Frank expand his role with Fresenius Medical Care. Frank has been working for us since 2009 and has an impressive experience in the health-care industry. He is an outstanding choice as his career and research interests have focused on the quality of care for chronic kidney disease patients.”
In his new role, Dr. Maddux will oversee the delivery of quality care to more than 140,000 dialysis patients across the United States, and will direct a number of clinical studies and initiatives programs designed to improve dialysis care in the future.
Dr. Maddux joined FMCNA in 2009 after the company acquired Health IT Services Group, a leading-edge Electronic Health Record software company that he founded in 2007. He has more than 25 years of experience in the health-care industry, including the practice of nephrology. Dr. Maddux also serves as Clinical Associate Professor of Medicine at the University of North Carolina School Of Medicine. He has served on numerous boards and committees involved in developing technology initiatives in both the medical and regional economic development arenas. Dr. Maddux received his bachelor’s degree in mathematics from Vanderbilt University and an MD degree from the University of North Carolina at Chapel Hill.
Dr. Maddux replaces Dr. Raymond Hakim, a true leader in the dialysis industry who helped FMCNA place a sharp focus on the highest quality patient care.
“Ray’s work resulted in substantial improvement in mortality as well as hospitalization rates during his tenure. We thank Ray for his many contributions and wish him the very best in the future,” said Rice Powell.
Jeffrey L. Hymes, M.D., has been named Senior Vice President and Associate Chief Medical Officer. In this new role, Dr. Hymes will report to Dr. Maddux. Dr. Hymes joined FMCNA in 2007. He is a graduate of Yale University and the Albert Einstein College of Medicine, and completed his internship and residency in Medicine at Yale-New Haven Hospital. Dr. Hymes was a fellow in the Clinical Nephrology department at the Boston University Medical Center and subsequently became a Clinical Instructor at the Boston University Medical Center, practicing nephrology in the Boston area. He has developed a large and extensive nephrology practice in the Nashville area, serving as President of Nephrology Associates in Nashville.
In addition Simon Castellanos, Executive Vice President and President of the North Division of Fresenius Medical Services (FMS), the company’s dialysis services division, will become Executive Vice President and President of FMS. He will continue to report to Rice Powell, Chief Executive Officer, who has been serving as Acting President of FMS. In this expanded role, Simon Castellanos will be responsible for the operations of more than 1,800 dialysis clinics across 48 states and Puerto Rico and will coordinate the efforts of the division’s four regional Presidents. Castellanos joined FMCNA in 2003 after working at Gambro Healthcare International where he held various finance positions, including Chief Financial Officer for the International Division.
“These key appointments position us well to meet the challenges ahead and to continue delivering world-class outcomes for our patients, employees and shareholders,” said Rice Powell. “The level of talent and experience that Frank, Jeff and Simon provide to our organization will serve to further strengthen our executive leadership team.”
About Fresenius Medical Care
Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to patient-oriented renal therapy. Through more than 2,900 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 228,000 patients worldwide. We are also the world's leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 2 million individuals worldwide. For more information about the company’s more than 1,800 U.S. dialysis facilities, visit www.ultracare-dialysis.com (in English and Spanish). For more information about Fresenius Medical Care, visit www.fmc-ag.com or www.fmcna.com
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.